Pfizer discontinues obesity drug danuglipron due to liver injury, maintaining Neutral rating

From Yahoo Finance: 2025-04-15 11:05:00

Pfizer discontinues oral GLP-1 obesity drug danuglipron due to liver injury in phase 1 study. Pfizer’s obesity pipeline now includes a GIP receptor antagonist in phase 2 and a phase 1 oral GLP-1 in T2D with Nxera Pharma. BofA suggests potential business development for Pfizer in obesity. BofA maintains a Neutral rating.

Source: TheFly

For more information on Pfizer, visit TipRanks for Disclaimer & Disclosure information or to Report an Issue.

Read more: BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged